Departments of Dermatology and Cutaneous Biology, and Biochemistry and Molecular Biology, Jefferson Medical College, and Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
J Invest Dermatol. 2012 Mar;132(3 Pt 2):820-8. doi: 10.1038/jid.2011.389. Epub 2011 Dec 8.
Tremendous progress has been made in the past two decades in molecular genetics of heritable skin diseases, and pathogenic mutations have been identified in as many as 500 distinct human genes. This progress has resulted in improved diagnosis with prognostic implications, has refined genetic counseling, and has formed the basis for prenatal and presymptomatic testing and preimplantation genetic diagnosis. However, there has been relatively little progress in developing effective and specific treatments for these often devastating diseases. However, very recently, a number of novel molecular strategies, including gene therapy, cell-based approaches, and protein replacement therapy, have been explored for the treatment of these conditions. This overview will focus on the prototypic heritable blistering disorders, epidermolysis bullosa, and related keratinopathies, in which significant progress has been made recently toward treatment, and it will illustrate how some of the translational research therapies have already entered the clinical arena.
在过去的二十年中,遗传性皮肤疾病的分子遗传学取得了巨大的进展,多达 500 个不同的人类基因已被确定为致病突变。这一进展改善了具有预后意义的诊断,完善了遗传咨询,并为产前、症状前检测和植入前遗传诊断奠定了基础。然而,在开发这些经常是毁灭性疾病的有效和特异性治疗方法方面,进展相对较少。然而,最近,许多新的分子策略,包括基因治疗、基于细胞的方法和蛋白质替代疗法,已经被探索用于这些疾病的治疗。本综述将重点介绍最近在治疗方面取得显著进展的典型遗传性水疱性疾病——大疱性表皮松解症和相关的角蛋白病,并说明一些转化研究疗法如何已经进入临床领域。